Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler.

MacGregor TR, ZuWallack R, Rubano V, Castles MA, Dewberry H, Ghafouri M, Wood CC.

Clin Transl Sci. 2016 Apr;9(2):105-13. doi: 10.1111/cts.12387. Epub 2016 Mar 6.

2.

Exposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.

Riggs MM, Seman LJ, Staab A, MacGregor TR, Gillespie W, Gastonguay MR, Woerle HJ, Macha S.

Br J Clin Pharmacol. 2014 Dec;78(6):1407-18. doi: 10.1111/bcp.12453.

3.

Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.

Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Königs C, Mensa FJ, Sabo JP, Yong CL, MacGregor TR, Nguyen T, Quinson AM.

Pediatr Infect Dis J. 2014 Jul;33(7):e173-9. doi: 10.1097/INF.0000000000000241.

PMID:
24378938
4.

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.

Riggs MM, Staab A, Seman L, MacGregor TR, Bergsma TT, Gastonguay MR, Macha S.

J Clin Pharmacol. 2013 Oct;53(10):1028-38. doi: 10.1002/jcph.147. Epub 2013 Aug 13.

PMID:
23940010
5.

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.

Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S.

Pharmacogenet Genomics. 2011 Nov;21(11):721-30. doi: 10.1097/FPC.0b013e32834a522e.

PMID:
21860339
6.

Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.

Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, Sabo JP, Dellamonica P.

J Clin Pharmacol. 2011 Jul;51(7):1071-8. doi: 10.1177/0091270010379808. Epub 2011 Jan 5.

PMID:
21209236
7.

"Forgiving" a missed daily dose.

Macgregor TR.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):345-6. doi: 10.1089/aid.2010.0273. Epub 2011 Feb 22. No abstract available.

8.

Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.

Huang F, Allen L, Huang DB, Moy F, Vinisko R, Nguyen T, Rowland L, MacGregor TR, Castles MA, Robinson P.

J Clin Pharm Ther. 2012 Feb;37(1):81-8. doi: 10.1111/j.1365-2710.2010.01235.x. Epub 2010 Dec 5.

PMID:
21128991
9.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.

10.

Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.

Sabo JP, Cong XJ, Kraft MF, Wallace L, Castles MA, Mauss S, MacGregor TR.

Eur J Clin Pharmacol. 2011 Mar;67(3):277-81. doi: 10.1007/s00228-010-0907-1. Epub 2010 Oct 12.

PMID:
20963404
11.

Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

Huang F, Scholl P, Huang DB, MacGregor TR, Vinisko R, Castles MA, Berger F, Robinson P.

J Clin Pharmacol. 2011 Jul;51(7):1061-70. doi: 10.1177/0091270010376971. Epub 2010 Aug 12.

PMID:
20705951
12.

Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, McCallister S.

HIV Clin Trials. 2010 Jan-Feb;11(1):28-38. doi: 10.1310/hct1101-28.

PMID:
20400409
13.

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD.

Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10.

14.

In vitro-in vivo correlation for nevirapine extended release tablets.

Macha S, Yong CL, Darrington T, Davis MS, MacGregor TR, Castles M, Krill SL.

Biopharm Drug Dispos. 2009 Dec;30(9):542-50. doi: 10.1002/bdd.691.

PMID:
19876936
15.

Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract.

Macha S, Yong CL, MacGregor TR, Castles M, Quinson AM, Rouyrre N, Wilding I.

J Clin Pharmacol. 2009 Dec;49(12):1417-25. doi: 10.1177/0091270009344856. Epub 2009 Sep 30.

PMID:
19793911
16.

Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.

Cammett AM, MacGregor TR, Wruck JM, Felizarta F, Miailhes P, Mallolas J, Piliero PJ.

Antimicrob Agents Chemother. 2009 Oct;53(10):4147-52. doi: 10.1128/AAC.00460-09. Epub 2009 Jul 20.

17.

Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Huang F, Drda K, MacGregor TR, Scherer J, Rowland L, Nguyen T, Ballow C, Castles M, Robinson P.

Antimicrob Agents Chemother. 2009 Jan;53(1):95-103. doi: 10.1128/AAC.00752-08. Epub 2008 Oct 27.

18.

Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

Huang F, Koenen-Bergmann M, Macgregor TR, Ring A, Hattox S, Robinson P.

Antimicrob Agents Chemother. 2008 Dec;52(12):4300-7. doi: 10.1128/AAC.00363-08. Epub 2008 Sep 29.

19.

Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):429-40. doi: 10.1097/QAI.0b013e318160a529.

PMID:
18176328
21.

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

Rowland LS, MacGregor TR, Campbell SJ, Jenkins R, Pearsall AB, Morris JP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):252-60. Epub 2007 Jun 22.

PMID:
17618842
22.

Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.

Chen L, Sabo JP, Philip E, Mao Y, Norris SH, MacGregor TR, Wruck JM, Garfinkel S, Castles M, Brinkman A, Valdez H.

Antimicrob Agents Chemother. 2007 Jul;51(7):2436-44. Epub 2007 May 7.

23.

Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.

Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH; 2NN Study Group.

HIV Clin Trials. 2005 Sep-Oct;6(5):254-61.

PMID:
16306032
24.

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(4):489-98.

PMID:
16038474
25.

Dipyridamole bioavailability in subjects with reduced gastric acidity.

Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert W.

J Clin Pharmacol. 2005 Jul;45(7):845-50.

PMID:
15951475
26.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group.

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
27.

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S.

HIV Clin Trials. 2004 Nov-Dec;5(6):371-82.

PMID:
15682350
28.

Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.

Sabo JP, Lamson MJ, Leitz G, Yong CL, MacGregor TR.

AAPS PharmSci. 2000;2(1):E1.

29.

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.

Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, Robinson P.

Biopharm Drug Dispos. 1999 Sep;20(6):285-91.

PMID:
10701699
30.

In vitro protein binding behavior of dipyridamole.

MacGregor TR, Sardi ED.

J Pharm Sci. 1991 Feb;80(2):119-20.

PMID:
2051312
31.

Efficacy of oral mexiletine therapy at a 12-h dosage interval.

Steen SN, Hughes EM, Sharon G, MacGregor TR.

Chest. 1990 Feb;97(2):358-63.

PMID:
1688758
32.

Clinical pharmacokinetics of clonidine.

Lowenthal DT, Matzek KM, MacGregor TR.

Clin Pharmacokinet. 1988 May;14(5):287-310. Review.

PMID:
3293868
33.

Relative bioavailability of chlorthalidone in humans after single oral doses.

Farina PR, MacGregor TR, Horhota ST, Keirns JJ.

J Pharm Sci. 1985 Sep;74(9):995-8.

PMID:
4067856
34.

Pharmacokinetics of transdermally delivered clonidine.

MacGregor TR, Matzek KM, Keirns JJ, van Wayjen RG, van den Ende A, van Tol RG.

Clin Pharmacol Ther. 1985 Sep;38(3):278-84.

PMID:
4028622
35.

Chlorthalidone pharmacodynamics in beagle dogs.

MacGregor TR, Keirns JJ, Farina PR, Matzek KM, Horhota ST, Esber HJ.

J Pharm Sci. 1985 Aug;74(8):851-6.

PMID:
4032269
36.

Pharmacokinetics of oral sustained release clonidine in humans.

MacGregor TR, Relihan GL, Keirns JJ.

Arzneimittelforschung. 1985;35(1A):440-6.

PMID:
4039184
37.

Analysis of chlorthalidone in biological fluids by high-performance liquid chromatography using a rapid column cleanup procedure.

MacGregor TR, Farina PR, Hagopian M, Hay N, Esber HJ, Keirns JJ.

Ther Drug Monit. 1984;6(1):83-90.

PMID:
6710559
38.

Isolation and characterization of metaproterenol-3-O-sulfate: a conjugate of metaproterenol in human urine.

MacGregor TR, Nastasi L, Farina PR, Keirns JJ.

Drug Metab Dispos. 1983 Nov-Dec;11(6):568-73.

PMID:
6140141
39.

Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs.

Macgregor TR, Drum MA, Harrigan SE, Wiley JN, Reuning RH.

J Pharm Pharmacol. 1983 Jan;35(1):38-42.

PMID:
6131962
40.

The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man.

Boxenbaum HG, Jodhka GS, Ferguson AC, Riegelman S, MacGregor TR.

J Pharmacokinet Biopharm. 1974 Jun;2(3):211-37. No abstract available.

PMID:
4452938

Supplemental Content

Loading ...
Support Center